Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00547612

Enrollment

Registered

2007-10-22

Start date

2007-09-30

Completion date

2008-12-31

Last updated

2012-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

adenocarcinoma of the pancreas, stage I pancreatic cancer, stage II pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, recurrent pancreatic cancer

Brief summary

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using \[18F\]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer. PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.

Detailed description

OBJECTIVES: * Determine whether \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan. OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive \[18F\]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours. Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.

Interventions

OTHERhigh performance liquid chromatography

OTHERpharmacological study

RADIATION[18F]-labeled substance P antagonist receptor quantifier

Study design

Allocation

NON_RANDOMIZED

Primary purpose

DIAGNOSTIC

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the pancreas * Primary or metastatic disease * At least one site of measurable disease * Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141 PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status 0-2 * WBC ≥ 1,200/mm³ * Creatinine \< 2.0 mg/dL * Negative pregnancy test * Fertile patients must agree to use effective contraception * Not pregnant or nursing

Exclusion criteria

* Allergy to IV contrast * Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan PRIOR CONCURRENT THERAPY: Inclusion criteria: * More than 4 weeks since prior abdominal surgery

Design outcomes

Primary

Measure	Time frame
Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026